Top

BMC Cancer

Published in:

Open Access 01-12-2021 | Colorectal Cancer | Research

Colorectal cancer survival among Ministry of National Guard-Health Affairs (MNG-HA) population 2009–2017: retrospective study

Authors: Mesnad Alyabsi, Fouad Sabatin, Majed Ramadan, Abdul Rahman Jazieh

Published in: BMC Cancer | Issue 1/2021

Abstract

Background

Colorectal cancer (CRC) is the most diagnosed cancer among males and third among females in Saudi Arabia, with up to two-third diagnosed at advanced stage. The objective of our study was to estimate CRC survival and determine prognostic factors.

Methods

Ministry of National Guard- Health Affairs (MNG-HA) registry data was utilized to identify patients diagnosed with CRC between 2009 and 2017. Cases were followed until December 30th, 2017 to assess their one-, three-, and five-year CRC-specific survivals. Kaplan-Meier method and Cox proportional hazard models were used to assess survival from CRC.

Results

A total of 1012 CRC patients were diagnosed during 2009–2017. Nearly, one-fourth of the patients presented with rectal tumor, 42.89% with left colon and 33.41% of the cases were diagnosed at distant metastasis stage. The overall one-, three-, and five-year survival were 83, 65 and 52.0%, respectively. The five-year survival was 79.85% for localized stage, 63.25% for regional stage and 20.31% for distant metastasis. Multivariate analyses showed that age, diagnosis period, stage, nationality, basis of diagnosis, morphology and location of tumor were associated with survival.

Conclusions

Findings reveal poor survival compared to Surveillance, Epidemiology, and End Results (SEER) population. Diagnoses at late stage and no surgical and/or perioperative chemotherapy were associated with increased risk of death. Population-based screening in this population should be considered.

Sung H, Ferlay J, Siegel R L, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.

World Health Organization: Cancer Country Profile 2020.

Alsanea N, Almadi MA, Abduljabbar AS, Alhomoud S, Alshaban TA, Alsuhaibani A, et al. National Guidelines for colorectal Cancer screening in Saudi Arabia with strength of recommendations and quality of evidence: tripartite task force from Saudi Society of Colon & rectal surgery, Saudi gastroenterology association and Saudi oncology society. Ann Saudi Med. 2015;35(3):189–95. https://doi.org/10.5144/0256-4947.2015.189.CrossRefPubMedPubMedCentral

Alyabsi M, Alhumaid A, Allah-Bakhsh H, Alkelya M, Aziz MA. Colorectal cancer in Saudi Arabia as the proof-of-principle model for implementing strategies of predictive, preventive, and personalized medicine in healthcare. EPMA Journal. 2020 Mar;11(1):119–31. https://doi.org/10.1007/s13167-019-00186-x.CrossRef

Althubiti MA, Eldein MM. Trends in the incidence and mortality of cancer in Saudi Arabia. Saudi Med J. 2018;39(12):1259–62. https://doi.org/10.15537/smj.2018.12.23348.CrossRefPubMedPubMedCentral

KFSHRC O.C.R.U: Tumor registry annual report 2015.

Bazarbashi S, Al Eid H, Minguet J. Cancer incidence in Saudi Arabia: 2012 data from the Saudi cancer registry. APJCP. 2017;18(9):2437–44. https://doi.org/10.22034/APJCP.2017.18.9.2437.CrossRefPubMedPubMedCentral

WorldHealth Organization: Cancer country profile - World Health Organization. 2014.

Alsanea N, Abduljabbar AS, Alhomoud S, Ashari LH, Hibbert D, Bazarbashi S. Colorectal cancer in Saudi Arabia: incidence, survival, demographics and implications for national policies. Ann Saudi Med. 2015;35(3):196–202. https://doi.org/10.5144/0256-4947.2015.196.CrossRefPubMedPubMedCentral

10.

Al-Ahwal MS, Shafik YH, Al-Ahwal HM. First national survival data for colorectal cancer among Saudis between 1994 and 2004: what’s next? BMC Public Health. 2013;13(1):1–6.CrossRef

11.

Aldiab A, Al Khayal KA, Al Obaid OA, Alsheikh A, Alsaleh K, Shahid M, et al. Clinicopathological features and predictive factors for colorectal cancer outcome in the Kingdom of Saudi Arabia. Oncology. 2017;92(2):75–86. https://doi.org/10.1159/000450857.CrossRefPubMed

12.

Siegel RL, Miller KD, Fedewa SA, Ahnen DJ, Meester RG, Barzi A, et al. Colorectal cancer statistics, 2017. CA Cancer J Clin. 2017;67(3):177–93.CrossRef

13.

Murphy G, Devesa SS, Cross AJ, Inskip PD, McGlynn KA, Cook MB. Sex disparities in colorectal cancer incidence by anatomic subsite, race and age. Int J Cancer. 2011;128(7):1668–75. https://doi.org/10.1002/ijc.25481.CrossRefPubMed

14.

Lee YC, Lee YL, Chuang JP, Lee JC. Differences in survival between colon and rectal cancer from SEER data. PLoS One. 2013 Nov 12;8(11):e78709. https://doi.org/10.1371/journal.pone.0078709.CrossRefPubMedPubMedCentral

15.

Chen VW, Hsieh MC, Charlton ME, Ruiz BA, Karlitz J, Altekruse SF, et al. Analysis of stage and clinical/prognostic factors for colon and rectal cancer from SEER registries: AJCC and collaborative stage data collection system. Cancer. 2014;120:3793–806. https://doi.org/10.1002/cncr.29056.CrossRefPubMed

16.

Young JL: SEER summary staging manual 2000: codes and coding instructions: National Cancer Institute, National Institutes of Health; 2001.

17.

von Allmen RS, Weiss S, Tevaearai HT, Kuemmerli C, Tinner C, Carrel TP, et al. Completeness of follow-up determines validity of study findings: results of a prospective repeated measures cohort study. PLoS One. 2015 Oct 15;10(10):e0140817. https://doi.org/10.1371/journal.pone.0140817.CrossRef

18.

Xue X, Agalliu I, Kim MY, Wang T, Lin J, Ghavamian R, Strickler HD. New methods for estimating follow-up rates in cohort studies. BMC Med Res Methodol 2017;17(1):1–0.

19.

Lark TG, Altman DG, De Stavola BL. Quantification of the completeness of follow-up. Lancet. 2002;359(9314):1309–10. https://doi.org/10.1016/S0140-6736(02)08272-7.CrossRef

20.

Elsamany SA, Alzahrani AS, Mohamed MM, Elmorsy SA, Zekri JE, Al-Shehri AS, et al. Clinico-pathological patterns and survival outcome of colorectal cancer in young patients: western Saudi Arabia experience. Asian Pac J Cancer Prev. 2014;15(13):5239–43. https://doi.org/10.7314/APJCP.2014.15.13.5239.CrossRefPubMed

21.

Bader T, Ismail A. Higher prevalence of KRAS mutations in colorectal cancer in Saudi Arabia: propensity for lung metastasis. Alexandria Journal of Medicine. 2014;50(3):203–9. https://doi.org/10.1016/j.ajme.2014.01.003.CrossRef

22.

Agüero F, Murta-Nascimento C, Gallén M, Andreu-García M, Pera M, Hernández C, et al. Colorectal cancer survival: results from a hospital-based cancer registry. Rev Esp Enferm Dig. 2012 Dec 1;104(11):572–7. https://doi.org/10.4321/S1130-01082012001100004.CrossRefPubMed

23.

Ramos M, Montano J, Esteva M, Barceló A, Franch P. Colorectal cancer survival by stage of cases diagnosed in Mallorca, Spain, between 2006 and 2011 and factors associated with survival. Cancer Epidemiol. 2016 Apr 1;41:63–70. https://doi.org/10.1016/j.canep.2016.01.001.CrossRef

24.

De Angelis R, Sant M, Coleman MP, Francisci S, Baili P, Pierannunzio D, et al. Cancer survival in Europe 1999–2007 by country and age: results of EUROCARE-5—a population-based study. Lancet Oncol. 2014;15(1):23–34. https://doi.org/10.1016/S1470-2045(13)70546-1.CrossRefPubMed

25.

Howlander N, Noone A, Krapcho M. SEER cancer statistics review (CSR) 1975-2016. National Cancer Institute website seer cancer Published online 2019.

26.

Allemani C, Rachet B, Weir HK, Richardson LC, Lepage C, Faivre J, Gatta G, Capocaccia R, Sant M, Baili P, Lombardo C. Colorectal cancer survival in the USA and Europe: a CONCORD high-resolution study. BMJ Open. 2013;3(9):e003055.

27.

Murphy CC, Sandler RS, Sanoff HK, Yang YC, Lund JL, Baron JA. Decrease in incidence of colorectal cancer among individuals 50 years or older after recommendations for population-based screening. Clin Gastroenterol Hepatol. 2017;15(6):903–9. https://doi.org/10.1016/j.cgh.2016.08.037.CrossRefPubMed

28.

Mosli MH, Al-Ahwal MS. Colorectal cancer in the Kingdom of Saudi Arabia: need for screening. Asian Pac J Cancer Prev. 2012;13(8):3809–13. https://doi.org/10.7314/APJCP.2012.13.8.3809.CrossRefPubMed

29.

Simillis C, Kalakouti E, Afxentiou T, Kontovounisios C, Smith JJ, Cunningham D, et al. Primary tumor resection in patients with incurable localized or metastatic colorectal cancer: a systematic review and meta-analysis. World J Surg. 2019 Jul;43(7):1829–40. https://doi.org/10.1007/s00268-019-04984-2.CrossRefPubMed

30.

Clancy C, Burke JP, Barry M, Kalady MF, Coffey JC. A meta-analysis to determine the effect of primary tumor resection for stage IV colorectal cancer with unresectable metastases on patient survival. Ann Surg Oncol. 2014;21(12):3900–8. https://doi.org/10.1245/s10434-014-3805-4.CrossRefPubMed

31.

Petrelli F, Coinu A, Ghilardi M, Cabiddu M, Zaniboni A, Barni S. Efficacy of oxaliplatin-based chemotherapy+ bevacizumab as first-line treatment for advanced colorectal cancer. Am J Clin Oncol. 2015;38(2):227–33. https://doi.org/10.1097/COC.0b013e3182a2d7b8.CrossRefPubMed

32.

Roder D, Karapetis CS, Wattchow D, Moore J, Singhal N, Joshi R, et al. Colorectal cancer treatment and survival: the experience of major public hospitals in South Australia over three decades. Asian Pac J Cancer Prev. 2015;16(6):2431–40. https://doi.org/10.7314/APJCP.2015.16.6.2431.CrossRefPubMed

33.

Lee KC, Ou YC, Hu WH, Liu CC, Chen HH. Meta-analysis of outcomes of patients with stage IV colorectal cancer managed with chemotherapy/radiochemotherapy with and without primary tumor resection. Onco Targets Ther. 2016;9:7059–69. https://doi.org/10.2147/OTT.S112965.CrossRefPubMedPubMedCentral

34.

Cho H, Mariotto AB, Schwartz LM, Luo J, Woloshin S. When do changes in cancer survival mean progress? The insight from population incidence and mortality. J Natl Cancer Inst Monogr. 2014;2014(49):187–97. https://doi.org/10.1093/jncimonographs/lgu014.CrossRefPubMedPubMedCentral

35.

Mariotto AB, Noone AM, Howlader N, Cho H, Keel GE, Garshell J, et al. Cancer survival: an overview of measures, uses, and interpretation. J Natl Cancer Inst Monogr. 2014;2014(49):145–86. https://doi.org/10.1093/jncimonographs/lgu024.CrossRefPubMedPubMedCentral

Title: Colorectal cancer survival among Ministry of National Guard-Health Affairs (MNG-HA) population 2009–2017: retrospective study
Authors: Mesnad Alyabsi
Fouad Sabatin
Majed Ramadan
Abdul Rahman Jazieh
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Colorectal Cancer
Colorectal Cancer
Published in: BMC Cancer / Issue 1/2021
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-021-08705-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

Protein deubiquitylase USP3 stabilizes Aurora A to promote proliferation and metastasis of esophageal squamous cell carcinoma

TFEB, SIRT1, CARM1, Beclin-1 expression and PITX2 methylation in breast cancer chemoresistance: a retrospective study

Pan-cancer evaluation of gene expression and somatic alteration data for cancer prognosis prediction

Cervical cancer screening patterns among HIV-positive women in Estonia: a population-based retrospective cohort study

Angiogenesis-related lncRNAs predict the prognosis signature of stomach adenocarcinoma

Soft tissue masses: distribution of entities and rate of malignancy in small lesions

Keynote webinar | Spotlight on antibody–drug conjugates in cancer